150L SUBSTITUTION – to find out the pattern of resistance mutations, including the 150L substitution, in patients who have failed an atazanavir-containing regimen
BIENESTAR – to examine the role of illicit drug use on nutritional status and outcomes, including antioxidant status, oxidative stress and liver dysfunction, in Hispanic, HIV-positive and HIV-negative, drug users and non-drug users – conducted in Spanish
CARE – to examine the risk of heart disease in HIV-infected individuals
CARE II – a follow-up to the CARE study to examine the risk of heart disease in HIV-infected individuals
CYTOCHROME – to investigate the effect of medications on a major liver enzyme
FRAM 2 – to investigate heart disease risk, body fat distribution, and how the body uses fats and sugars in HIV-infected people. This is a follow-up of FRAM 1, a multi-site study of nearly 1,200 patients.
LIPID - to
examine the relationship between insulin resistance and changes in body fat distribution in HIV-infected persons
DIET – to examine in patients with elevated triglycerides the effect of a diet intervention that is high in omega-3 fatty acids and fiber and low in glycemic index on the metabolic changes associated with HIV lipodystrophy
HALO – to asses the safety and effectiveness of Omacor® (Omega-3 fats or fish oil) on lipids in HIV positive individuals
KALETRA MONOTHERAPY – to determine whether taking Kaletra as a single anti-HIV drug will provide an effective regimen with few side effects
SWITCH - to investigate an antiretroviral drug switch intervention for fat atrophy
TH9507 - to determine if TH9507 is effective and safe at reducing visceral adipose tissue (excess abdominal fat) in people with HIV-associated adipose redistribution syndrome (HARS).
TH9507-CTR-1011 - a follow-up to the TH9507 study to determine if TH9507 is effective and safe at reducing visceral adipose tissue (excess abdominal fat) in people with HIV-associated adipose redistribution syndrome (HARS).
Privacy and confidentiality are strictly maintained.
